Moreover, Rad51ap1 deficiency abrogates tumor growth and metastasis in a breast cancer mouse model (Bridges et al., 2020), suggesting that the RAD51AP1 protein may be a promising target of inhibition in anti-cancer therapy. This evidence concerns the gene RAD51AP1 and breast carcinoma.